NiCox and Pfizer launch glaucoma trial

Article

NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.

NicOx and Pfizer have initiated a dose-ranging Phase II clinical study of PF-03187207, a treatment for glaucoma, in Japan.

PF-03187207 is the lead development compound generated under the collaboration between Pfizer and NicOx, which is concentrating on the research and development of nitric oxide-donating prostaglandin F2-alpha analogues for the treatment of glaucoma.

The Japanese study will compare the safety and efficacy of the PF-03187207 with latanoprost (Xalatan; Pfizer). The compound is already being examined in a Phase II proof-of-concept study in the US.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.